The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation
K T Park(Lucile Packard Children's Hospital), Caren Heller(Crohn's and Colitis Foundation), Orna Ehrlich(Crohn's and Colitis Foundation), Kim Henrichsen(Centene Corporation (United States)), Perry Meadows(Geisinger Health System), David T. Rubin(University of California System), Nicole Engel-Nitz(Optum (United States)), Sandra C. Kim(Children's Hospital of Pittsburgh), Sean M. Murphy(Cornell University), John I. Allen(University of Michigan), Miguel Regueiro(Cleveland Clinic), Eva Szigethy(University of Pittsburgh Medical Center), Rachel Lawton(Cincinnati Children's Hospital Medical Center)
Cited by 426
Related Papers
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k